Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Deffered Revenue (2016 - 2025)

Arrowhead Pharmaceuticals' Non-Current Deffered Revenue history spans 9 years, with the latest figure at $53.8 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $53.8 million; the TTM value through Dec 2025 reached $53.8 million, changed N/A, while the annual FY2022 figure was $56.0 million, 57.45% down from the prior year.
  • Non-Current Deffered Revenue reached $53.8 million in Q4 2025 per ARWR's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $131.5 million in Q3 2021 to a low of $1.1 million in Q1 2023.
  • Average Non-Current Deffered Revenue over 4 years is $75.2 million, with a median of $75.5 million recorded in 2021.
  • Peak YoY movement for Non-Current Deffered Revenue: dropped 10.77% in 2022, then tumbled 98.8% in 2023.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $106.5 million in 2021, then tumbled by 61.69% to $40.8 million in 2022, then crashed by 97.36% to $1.1 million in 2023, then surged by 4906.98% to $53.8 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Non-Current Deffered Revenue are $53.8 million (Q4 2025), $1.1 million (Q1 2023), and $40.8 million (Q4 2022).